Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Next Previous
Trial Profile

A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LB-2102 (Primary)
  • Indications Neuroendocrine carcinoma; Small cell lung cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 03 Jun 2025 According to a Legend Biotech media release, interim results presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 22 May 2025 According to a Legend Biotech media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30-June 3, 2025.
  • 13 May 2025 According to a Legend Biotech USA media release, License revenue was $9.3 million for the three months ended March 31, 2025, compared to $12.2 million for the three months ended March 31, 2024. The decrease of $2.9 million was solely attributed to revenue recognized pursuant to Legend Biotech's license agreement with Novartis for the development, manufacture, and commercialization of LB2102 and other potential CAR-T therapies selectively targeting DLL-3 (the Novartis License Agreement). This

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top